BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 12745658)

  • 1. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
    Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
    Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
    Richardson PG; Murakami C; Jin Z; Warren D; Momtaz P; Hoppensteadt D; Elias AD; Antin JH; Soiffer R; Spitzer T; Avigan D; Bearman SI; Martin PL; Kurtzberg J; Vredenburgh J; Chen AR; Arai S; Vogelsang G; McDonald GB; Guinan EC
    Blood; 2002 Dec; 100(13):4337-43. PubMed ID: 12393437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.
    Salat C; Holler E; Kolb HJ; Reinhardt B; Pihusch R; Wilmanns W; Hiller E
    Blood; 1997 Mar; 89(6):2184-8. PubMed ID: 9058743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study.
    Chopra R; Eaton JD; Grassi A; Potter M; Shaw B; Salat C; Neumeister P; Finazzi G; Iacobelli M; Bowyer K; Prentice HG; Barbui T
    Br J Haematol; 2000 Dec; 111(4):1122-9. PubMed ID: 11167751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defibrotide in the prevention and treatment of veno-occlusive disease in autologous and allogeneic stem cell transplantation in children.
    Qureshi A; Marshall L; Lancaster D
    Pediatr Blood Cancer; 2008 Apr; 50(4):831-2. PubMed ID: 18286502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defibrotide as salvage therapy for refractory veno-occlusive disease of the liver complicating allogeneic bone marrow transplantation.
    Abecasis MM; Conceição Silva JP; Ferreira I; Guimarães A; Machado A
    Bone Marrow Transplant; 1999 Apr; 23(8):843-6. PubMed ID: 10231151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population.
    Richardson PG; Elias AD; Krishnan A; Wheeler C; Nath R; Hoppensteadt D; Kinchla NM; Neuberg D; Waller EK; Antin JH; Soiffer R; Vredenburgh J; Lill M; Woolfrey AE; Bearman SI; Iacobelli M; Fareed J; Guinan EC
    Blood; 1998 Aug; 92(3):737-44. PubMed ID: 9680339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: update on defibrotide and other current investigational therapies.
    Ho VT; Revta C; Richardson PG
    Bone Marrow Transplant; 2008 Feb; 41(3):229-37. PubMed ID: 17994121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation.
    Salat C; Holler E; Kolb HJ; Pihusch R; Reinhardt B; Penovici M; Ledderose G; Hiller E
    Leuk Lymphoma; 1999 Mar; 33(1-2):25-32. PubMed ID: 10194118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Veno-occlusive disease in pediatric patients affected by Wilms tumor.
    Cesaro S; Spiller M; Sartori MT; Alaggio R; Peruzzo M; Saggiorato G; Bisogno G
    Pediatr Blood Cancer; 2011 Aug; 57(2):258-61. PubMed ID: 21246705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
    Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
    Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
    Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease.
    Salat C; Holler E; Reinhardt B; Kolb HJ; Seeber B; Ledderose G; Mittermueller J; Duell T; Wilmanns W; Hiller E
    Bone Marrow Transplant; 1994 Nov; 14(5):747-50. PubMed ID: 7889007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Late-onset hepatic veno-occlusive disease post autologous peripheral stem cell transplantation successfully treated with oral defibrotide.
    Shah MS; Jeevangi NK; Joshi A; Khattry N
    J Cancer Res Ther; 2009; 5(4):312-4. PubMed ID: 20160371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
    Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
    J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: review and update on the use of defibrotide.
    Ho VT; Linden E; Revta C; Richardson PG
    Semin Thromb Hemost; 2007 Jun; 33(4):373-88. PubMed ID: 17525895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
    Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
    Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years.
    Kalayoglu-Besisik S; Yenerel MN; Caliskan Y; Ozturk S; Besisik F; Sargin D
    Transplant Proc; 2005 Jun; 37(5):2285-9. PubMed ID: 15964400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
    Lee JH; Lee KH; Lee JH; Kim S; Seol M; Park CJ; Chi HS; Kang W; Kim ST; Kim WK; Lee JS
    Br J Haematol; 2002 Sep; 118(4):1087-94. PubMed ID: 12199790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation.
    Gerecitano J; Mathias C; Mick R; Duffy KM; Luger S; Stadtmauer EA; Schuster SJ; Tsai D; Nasta S; Berlin J; Phillips DK; High KA; Porter DL
    J Hematother Stem Cell Res; 2003 Apr; 12(2):215-23. PubMed ID: 12804180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.